Glioblastoma — clinical trials in Italy
21 open options
- TRIALPHASE2RECRUITING
Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM).
Radiotherapy, Temozolomide, Doxorubicin — 1 site
- TRIALNARECRUITING
Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study.
18F-GE-180 PET · Advanced MRI · Collection of hematopoietic stem cells — 1 site
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 55 sites
- TRIALPHASE3RECRUITING
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Lomustine · Reirradiation — 45 sites
- TRIALPHASE2RECRUITING
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma
Autologous Dendritic Cells (DC) vaccine · Temozolomide — 1 site
- TRIALNANOT_YET_RECRUITING
Patient's Derived Organoids for Drug Screening in Glioblastoma
Development and characterization of PDOs · Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs — 1 site
- TRIALPHASE2RECRUITING
Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
Metformin · Radiation IMRT · Temozolomide — 7 sites
- TRIALNARECRUITING
Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life
Resting State Functional Magnetic Resonance Imaging (rs-fMRI) · Up-front Motor Rehabilitation · Up-front Chemotherapy — 1 site
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 57 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Oral repotrectinib (TPX-0005) — 68 sites
- TRIALNARECRUITING
Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)
Neoaddjuvant Stereotactic Radiotherapy with Simultaneous Integrated Boost — 1 site
- TRIALPHASE2RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
APL-101 Oral Capsules — 35 sites
- TRIALPHASE3RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Optune® device · Temozolomide · Pembrolizumab — 102 sites
- TRIALNARECRUITING
Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma
Biological biomarker analysis — 1 site
- TRIALNARECRUITING
Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients
Silibinin as STAT3 inhibitor · Placebo — 16 sites
- TRIALPHASE1RECRUITING
GD2-CAR T Cells for Pediatric Brain Tumours
GD2-CART01 (iC9-GD2-CAR T-cells) — 1 site
- TRIALPHASE2RECRUITING
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
Metformin — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
BAY 3713372 — 60 sites
- TRIALPHASE1RECRUITING
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
PhOx430 · PhOx430 — 4 sites
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Niraparib and Temozolomide in Patients Glioblastoma
Temodal · Niraparib — 1 site
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Plixorafenib — 70 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.